250 related articles for article (PubMed ID: 15201577)
1. Increased production of granulocyte-macrophage colony-stimulating factor in Crohn's disease--a possible target for infliximab treatment.
Agnholt J; Kelsen J; Brandsborg B; Jakobsen NO; Dahlerup JF
Eur J Gastroenterol Hepatol; 2004 Jul; 16(7):649-55. PubMed ID: 15201577
[TBL] [Abstract][Full Text] [Related]
2. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease.
Di Sabatino A; Ciccocioppo R; Cinque B; Millimaggi D; Morera R; Ricevuti L; Cifone MG; Corazza GR
Gut; 2004 Jan; 53(1):70-7. PubMed ID: 14684579
[TBL] [Abstract][Full Text] [Related]
3. Infliximab: mechanism of action beyond TNF-alpha neutralization in inflammatory bowel disease.
Kirman I; Whelan RL; Nielsen OH
Eur J Gastroenterol Hepatol; 2004 Jul; 16(7):639-41. PubMed ID: 15201575
[TBL] [Abstract][Full Text] [Related]
4. Response, relapse and mucosal immune regulation after infliximab treatment in fistulating Crohn's disease.
Agnholt J; Dahlerup JF; Buntzen S; Tøttrup A; Nielsen SL; Lundorf E
Aliment Pharmacol Ther; 2003 Mar; 17(5):703-10. PubMed ID: 12641520
[TBL] [Abstract][Full Text] [Related]
5. Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease.
Van den Brande JM; Koehler TC; Zelinkova Z; Bennink RJ; te Velde AA; ten Cate FJ; van Deventer SJ; Peppelenbosch MP; Hommes DW
Gut; 2007 Apr; 56(4):509-17. PubMed ID: 17082252
[TBL] [Abstract][Full Text] [Related]
6. Infliximab reduces the number of activated mucosal lymphocytes in patients with Crohn's disease.
Ferkolj I; Ihan A; Markovic S; Veceric Z; Pohar M
J Gastrointestin Liver Dis; 2006 Sep; 15(3):231-5. PubMed ID: 17013447
[TBL] [Abstract][Full Text] [Related]
7. The effect of etanercept and infliximab on the production of tumour necrosis factor alpha, interferon-gamma and GM-CSF in in vivo activated intestinal T lymphocyte cultures.
Agnholt J; Dahlerup JF; Kaltoft K
Cytokine; 2003 Aug; 23(3):76-85. PubMed ID: 12906870
[TBL] [Abstract][Full Text] [Related]
8. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis.
Baert FJ; D'Haens GR; Peeters M; Hiele MI; Schaible TF; Shealy D; Geboes K; Rutgeerts PJ
Gastroenterology; 1999 Jan; 116(1):22-8. PubMed ID: 9869598
[TBL] [Abstract][Full Text] [Related]
9. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease.
Cornillie F; Shealy D; D'Haens G; Geboes K; Van Assche G; Ceuppens J; Wagner C; Schaible T; Plevy SE; Targan SR; Rutgeerts P
Aliment Pharmacol Ther; 2001 Apr; 15(4):463-73. PubMed ID: 11284774
[TBL] [Abstract][Full Text] [Related]
10. Reduction of CD68+ macrophages and decreased IL-17 expression in intestinal mucosa of patients with inflammatory bowel disease strongly correlate with endoscopic response and mucosal healing following infliximab therapy.
Caprioli F; Bosè F; Rossi RL; Petti L; Viganò C; Ciafardini C; Raeli L; Basilisco G; Ferrero S; Pagani M; Conte D; Altomare G; Monteleone G; Abrignani S; Reali E
Inflamm Bowel Dis; 2013; 19(4):729-39. PubMed ID: 23448791
[TBL] [Abstract][Full Text] [Related]
11. Genetic and Transcriptomic Variation Linked to Neutrophil Granulocyte-Macrophage Colony-Stimulating Factor Signaling in Pediatric Crohn's Disease.
Denson LA; Jurickova I; Karns R; Shaw KA; Cutler DJ; Okou D; Valencia CA; Dodd A; Mondal K; Aronow BJ; Haberman Y; Linn A; Price A; Bezold R; Lake K; Jackson K; Walters TD; Griffiths A; Baldassano RN; Noe JD; Hyams JS; Crandall WV; Kirschner BS; Heyman MB; Snapper S; Guthery SL; Dubinsky MC; Leleiko NS; Otley AR; Xavier RJ; Stevens C; Daly MJ; Zwick ME; Kugathasan S
Inflamm Bowel Dis; 2019 Feb; 25(3):547-560. PubMed ID: 30124884
[TBL] [Abstract][Full Text] [Related]
12. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease.
ten Hove T; van Montfrans C; Peppelenbosch MP; van Deventer SJ
Gut; 2002 Feb; 50(2):206-11. PubMed ID: 11788561
[TBL] [Abstract][Full Text] [Related]
13. Granulocyte-macrophage colony-stimulating factor elicits bone marrow-derived cells that promote efficient colonic mucosal healing.
Bernasconi E; Favre L; Maillard MH; Bachmann D; Pythoud C; Bouzourene H; Croze E; Velichko S; Parkinson J; Michetti P; Velin D
Inflamm Bowel Dis; 2010 Mar; 16(3):428-41. PubMed ID: 19639560
[TBL] [Abstract][Full Text] [Related]
14. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC.
Ferrante M; Colombel JF; Sandborn WJ; Reinisch W; Mantzaris GJ; Kornbluth A; Rachmilewitz D; Lichtiger S; D'Haens GR; van der Woude CJ; Danese S; Diamond RH; Oortwijn AF; Tang KL; Miller M; Cornillie F; Rutgeerts PJ;
Gastroenterology; 2013 Nov; 145(5):978-986.e5. PubMed ID: 23954314
[TBL] [Abstract][Full Text] [Related]
15. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease.
Geboes K; Rutgeerts P; Opdenakker G; Olson A; Patel K; Wagner CL; Marano CW
Curr Med Res Opin; 2005 Nov; 21(11):1741-54. PubMed ID: 16307694
[TBL] [Abstract][Full Text] [Related]
16. Successful granulocyte-colony stimulating factor treatment of Crohn's disease is associated with the appearance of circulating interleukin-10-producing T cells and increased lamina propria plasmacytoid dendritic cells.
Mannon PJ; Leon F; Fuss IJ; Walter BA; Begnami M; Quezado M; Yang Z; Yi C; Groden C; Friend J; Hornung RL; Brown M; Gurprasad S; Kelsall B; Strober W
Clin Exp Immunol; 2009 Mar; 155(3):447-56. PubMed ID: 19094118
[TBL] [Abstract][Full Text] [Related]
17. [Infliximab in the treatment of patients with Crohn's disease: preliminary report].
Gellona V J; Zarraonandia A A; Zúñiga D A; Palma C R; Contreras P J; Silva Ch J; González D R; Quintana V C
Rev Med Chil; 2006 Mar; 134(3):320-5. PubMed ID: 16676104
[TBL] [Abstract][Full Text] [Related]
18. Mucosal healing of ileal lesions is associated with long-term clinical remission after infliximab maintenance treatment in patients with Crohn's disease.
Beppu T; Ono Y; Matsui T; Hirai F; Yano Y; Takatsu N; Ninomiya K; Tsurumi K; Sato Y; Takahashi H; Ookado Y; Koga A; Kinjo K; Nagahama T; Hisabe T; Takaki Y; Yao K
Dig Endosc; 2015 Jan; 27(1):73-81. PubMed ID: 24833527
[TBL] [Abstract][Full Text] [Related]
19. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
[TBL] [Abstract][Full Text] [Related]
20. Increased secretion of granulocyte-macrophage colony-stimulating factor in mucosal lesions of inflammatory bowel disease.
Noguchi M; Hiwatashi N; Liu ZX; Toyota T
Digestion; 2001; 63 Suppl 1():32-6. PubMed ID: 11173907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
